
Mirtazapine
Mirtazapine is an established antidepressant. A network meta-analysis of 522 trials found all 21 antidepressants studied, including mirtazapine, more effective than placebo for adult depression, and mirtazapine was among those that did better in head-to-head trials. A Cochrane review found it worked faster than SSRIs at 2 weeks but caused more weight gain and sleepiness. Alcohol, St. John's wort and tryptophan are the high-severity interactions: alcohol adds to drowsiness and impaired coordination, and the two supplements raise serotonin syndrome risk.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults with major depressive disorder whose prescriber recommends mirtazapine, for example when sleep problems or poor appetite are part of the picture
Common dosing range
Set by your prescriber. The Remeron label starts at 15 mg once daily, preferably in the evening before sleep, with increases up to a maximum of 45 mg a day, no more often than every 1 to 2 weeks
When to expect effects
Label trials lasted 6 weeks; the Cochrane review found more responders than with SSRIs already at 2 weeks
Watch out for
Boxed warning for suicidal thoughts and behaviors in children, teens and young adults. Avoid alcohol and benzodiazepines. Never combine with MAO inhibitors. Rarely causes agranulocytosis: report fever, sore throat or mouth sores. Do not stop suddenly
What is it
Mirtazapine is a prescription antidepressant with a tetracyclic structure, sold as generic tablets, Remeron film-coated tablets (15 mg and 30 mg) and RemeronSolTab orally disintegrating tablets (15, 30 and 45 mg). The Remeron label approves it for major depressive disorder in adults only; it is not approved for children. It is known for causing sleepiness and increased appetite with weight gain. Its boxed warning covers suicidal thoughts and behaviors in young people. For supplements and drinks, alcohol is the high-severity interaction on this page and saffron a low-severity one.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
major depressive disorder in adults Good Evidence | Modest; response odds about 1.4 to 2.1 times placebo across antidepressants | Adults with major depressive disorder, without bipolar or psychotic features | Acute treatment trials lasting weeks |
speed of response compared with other antidepressants Limited Evidence | Small to moderate; odds of response 1.57 times SSRIs at 2 weeks and 1.19 times at 6 to 12 weeks | Adults with major depression for whom a faster early response matters and weight gain is acceptable | Differences seen from 2 weeks |
major depressive disorder in adults
- Effect
- Modest; response odds about 1.4 to 2.1 times placebo across antidepressants
- Best fit
- Adults with major depressive disorder, without bipolar or psychotic features
- Time
- Acute treatment trials lasting weeks
speed of response compared with other antidepressants
- Effect
- Small to moderate; odds of response 1.57 times SSRIs at 2 weeks and 1.19 times at 6 to 12 weeks
- Best fit
- Adults with major depression for whom a faster early response matters and weight gain is acceptable
- Time
- Differences seen from 2 weeks
Evidence for 2 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
major depressive disorder in adults
Disease adjunctA 2018 network meta-analysis of 522 double-blind trials with 116,477 adults found that all 21 antidepressants studied, including mirtazapine, were more effective than placebo for acute treatment of major depression, with odds ratios from 1.37 to 2.13. In head-to-head trials, mirtazapine was among the drugs that were more effective than other antidepressants (odds ratios 1.19 to 1.96 for that group). The authors rated the certainty of evidence moderate to very low. Trials with many people with bipolar, psychotic or treatment-resistant depression were excluded.
Bottom line: Mirtazapine works better than placebo for adult depression and did well in head-to-head comparisons.
speed of response compared with other antidepressants
Disease adjunctA 2011 Cochrane review of 29 randomized trials (4,974 adults), mostly 6-week outpatient studies with poorly reported risk of bias, compared mirtazapine with other antidepressants. Against SSRIs, mirtazapine gave more responders at 2 weeks (odds ratio 1.57) and at the end of acute treatment (odds ratio 1.19). Against tricyclic antidepressants there was no clear difference. Dropout rates were similar, but mirtazapine caused more weight gain, increased appetite and sleepiness than SSRIs, and less nausea, vomiting and sexual dysfunction.
Bottom line: Mirtazapine may work somewhat faster than SSRIs, with a different side-effect profile: more weight gain and sleepiness, less nausea and sexual dysfunction.
How it works
How to take it
What to track
Bottom line: Your prescriber sets the dose; take it once in the evening, avoid alcohol, and do not stop suddenly on your own.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Suicidal thoughts and behaviors (boxed warning). In pooled trials, antidepressants increased these in people under 25 (14 extra cases per 1,000 under 18 and 5 per 1,000 aged 18 to 24); everyone taking mirtazapine should be watched for worsening, especially in the first months and after dose changes.
Agranulocytosis: in premarketing trials, 2 of 2,796 patients developed agranulocytosis and a third severe neutropenia; all recovered after stopping. Sore throat, fever, mouth sores or other signs of infection with a low white count mean the drug should be stopped.
Serotonin syndrome, a potentially life-threatening reaction, especially with other serotonergic products (triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, St. John's wort) or MAO inhibitors; it can also occur with mirtazapine alone.
Serious skin reactions, including DRESS, Stevens-Johnson syndrome and toxic epidermal necrolysis, which can be fatal; QT prolongation and Torsades de Pointes, mostly in overdose or with other QT-prolonging drugs.
Other label warnings: angle-closure glaucoma in people with untreated narrow eye angles, activation of mania or hypomania, seizures, low blood sodium (sometimes below 110 mmol/L, more likely in older adults and people on diuretics), liver enzyme rises (ALT 3 or more times normal in 2.0% versus 0.3% on placebo), dizziness on standing, and discontinuation symptoms after abrupt stopping.
Who should avoid it
- People taking an MAO inhibitor or within 14 days of stopping one, including linezolid or intravenous methylene blue (contraindicated)
- People with known hypersensitivity to mirtazapine or its ingredients (contraindicated)
- Children and teens: not approved; two placebo-controlled trials in 258 pediatric patients did not establish safety and effectiveness, and 49% of treated children gained at least 7% of body weight in 8 weeks
- People with phenylketonuria using RemeronSolTab: each orally disintegrating tablet contains phenylalanine (2.6 mg in 15 mg, 5.2 mg in 30 mg, 7.8 mg in 45 mg)
Pregnancy & breastfeeding
Pregnancy: the Remeron label says long experience in pregnant women, from published observational studies and postmarketing reports, has not reliably identified a drug-associated risk of major birth defects, miscarriage or other harmful outcomes. Women who stop antidepressants during pregnancy are more likely to relapse, so the risks of untreated depression also count. A national pregnancy registry for antidepressants collects outcomes. Breastfeeding: mirtazapine passes into breast milk at low levels, with relative infant doses of 0.6% to 2.8% of the mother's weight-adjusted dose, and no adverse effects were reported in most breastfed infants. The label says to weigh the benefits of breastfeeding against the mother's need for mirtazapine and any possible effects on the infant.
Interactions
Contraindicated because of the risk of serotonin syndrome. The label requires at least 14 days between stopping an MAOI and starting mirtazapine, and at least 14 days after stopping mirtazapine before starting an MAOI.
The Remeron label says alcohol adds to the impairment of thinking and motor skills that mirtazapine causes on its own, and that alcohol should be avoided during treatment. In a small label study, alcohol barely changed mirtazapine blood levels, so the risk is the added effect, not a higher drug level. Avoid alcohol while taking mirtazapine, do not drive if you feel drowsy, and discuss your drinking with your prescriber or pharmacist.
The label says combining serotonergic drugs with mirtazapine increases the risk of serotonin syndrome and calls for monitoring, especially when starting or raising a dose. Seek urgent care for agitation, tremor, fever, fast heartbeat, heavy sweating or muscle stiffness.
The label says benzodiazepines add to mirtazapine's impairment of thinking and motor skills and that the combination should be avoided. Talk to your prescriber if you take one for anxiety or sleep.
The label lists St. John's Wort among serotonergic products that raise the risk of serotonin syndrome with mirtazapine, particularly when treatment starts or the dose goes up. No published case with this exact pair was found, and a change in mirtazapine levels from the herb has not been shown. Do not add it unless your prescriber advises it, and seek urgent care for agitation, tremor, fever, fast heartbeat, heavy sweating or muscle stiffness.
The label lists tryptophan among serotonergic products that raise the risk of serotonin syndrome with mirtazapine, particularly when treatment starts or the dose goes up. No published case with this exact pair was found; the warning rests on the label and the shared effect on serotonin. Do not add a tryptophan supplement unless your prescriber advises it.
A 2023 systematic review of laboratory, animal and human research lists blocking the reuptake of dopamine, norepinephrine and serotonin among saffron's proposed mechanisms, which raises a theoretical concern about added serotonin effects. No trial has tested saffron with mirtazapine. In a placebo-controlled trial in 160 adults already taking an antidepressant, a standardized saffron extract (14 mg twice daily) for 8 weeks improved clinician-rated depression scores, but not self-rated scores, without increasing antidepressant side effects; its abstract does not name the antidepressants taken. The only trial that names them, a 4-week pilot in 40 adults, added crocin, a saffron compound, to the SSRIs fluoxetine, sertraline or citalopram. Discuss it with your prescriber before adding saffron.
Documented interactions
Evidence-graded pair pages with sources, dosing notes, and timing guidance, a complement to the narrative section above.
Warnings (3)
+ alcohol
highMirtazapine and alcohol both depress the central nervous system, producing additive sedation, drowsiness, and impaired coordination and judgment. Mirtazapine's strong H1-antihistamine activity makes the sedative interaction with alcohol particularly pronounced, and the FDA label specifically advises avoiding alcohol during treatment.
+ st. john's wort
highMirtazapine is an antidepressant that enhances serotonin activity in the brain, and its label counts St. John's wort among the serotonergic products that add to that effect. The Remeron label says the risk of serotonin syndrome, a potentially life-threatening reaction, is increased when mirtazapine is used with other serotonergic drugs and names St. John's Wort in that list. The warning rests on the label and the shared effect on serotonin: no published case of serotonin syndrome from this exact pair was found, and whether the herb changes mirtazapine blood levels has not been established.
+ tryptophan
highMirtazapine is an antidepressant that enhances serotonin activity, and L-tryptophan is the amino acid the body turns into serotonin. The Remeron label lists tryptophan among the serotonergic products that raise the risk of serotonin syndrome, a potentially life-threatening reaction, particularly when treatment starts or the dose goes up. The warning rests on the label and the shared mechanism: no published case of serotonin syndrome from this exact pair was found.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Can I drink alcohol while taking mirtazapine?⌄
The Remeron label says to avoid alcohol. Alcohol adds to the drowsiness and impaired coordination and judgment that mirtazapine causes, and this page rates the pair high. If you drink, talk to your prescriber or pharmacist, and do not drive if you feel drowsy.
Can I take saffron supplements with mirtazapine?⌄
The concern is theoretical. A review lists blocking serotonin reuptake among saffron's proposed mechanisms, but no trial has tested it with mirtazapine. One trial added a saffron extract to unnamed antidepressants and found antidepressant side effects did not get worse; a small pilot added a saffron compound, crocin, to the SSRIs fluoxetine, sertraline or citalopram, and its abstract does not report side-effect results. This page rates the pair low severity. Ask your prescriber before starting it.
Is it safe to take St. John's wort or tryptophan with mirtazapine?⌄
Ask your prescriber first. The Remeron label lists St. John's wort and tryptophan among serotonergic products that raise the risk of serotonin syndrome when combined with mirtazapine.
Why does mirtazapine make me sleepy and hungry?⌄
The label links its sleepiness to strong blocking of histamine H1 receptors. In 6-week trials, 54% of people reported sleepiness and 17% increased appetite, and 12% reported weight gain. The label advises caution with driving until you know how it affects you.
What happens if I stop mirtazapine suddenly?⌄
Stopping, especially abruptly, can cause dizziness, abnormal dreams, electric-shock sensations, agitation, anxiety, nausea and sweating. The label recommends a gradual reduction. Talk to your prescriber before making any change.
References by claim
Track Mirtazapine with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
